Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 30.7 Thousand USD | 239.03% |
| 2022 | -22.08 Thousand USD | -112.07% |
| 2021 | 183.03 Thousand USD | 1178.97% |
| 2020 | -16.96 Thousand USD | 0.0% |
| 2019 | -16.96 Thousand USD | -43.64% |
| 2018 | -11.81 Thousand USD | 97.86% |
| 2017 | -551.19 Thousand USD | -2839.73% |
| 2016 | -18.75 Thousand USD | 2.47% |
| 2015 | -19.22 Thousand USD | 0.0% |
| 2010 | 36.96 Thousand USD | 151.35% |
| 2009 | 14.7 Thousand USD | 158.62% |
| 2008 | 5687.00 USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -5522.00 USD | 0.0% |
| 2024 Q2 | -5522.00 USD | 0.0% |
| 2023 Q3 | 73.9 Thousand USD | 116.94% |
| 2023 FY | 30.7 Thousand USD | 239.03% |
| 2023 Q1 | -5522.00 USD | 67.52% |
| 2023 Q2 | 34.06 Thousand USD | 716.95% |
| 2022 Q2 | -2825.00 USD | -24.83% |
| 2022 FY | -22.08 Thousand USD | -112.07% |
| 2022 Q4 | -17 Thousand USD | 0.0% |
| 2022 Q3 | - USD | 100.0% |
| 2022 Q1 | -2263.00 USD | 0.0% |
| 2021 FY | 183.03 Thousand USD | 1178.97% |
| 2021 Q1 | -4476.00 USD | -5.54% |
| 2021 Q2 | 200 Thousand USD | 4568.28% |
| 2021 Q3 | -9200.00 USD | -104.6% |
| 2020 Q4 | -4241.00 USD | 0.0% |
| 2020 FY | -16.96 Thousand USD | 0.0% |
| 2019 FY | -16.96 Thousand USD | -43.64% |
| 2018 FY | -11.81 Thousand USD | 97.86% |
| 2017 FY | -551.19 Thousand USD | -2839.73% |
| 2016 FY | -18.75 Thousand USD | 2.47% |
| 2015 FY | -19.22 Thousand USD | 0.0% |
| 2011 Q1 | 6218.00 USD | -46.33% |
| 2011 Q2 | 15.35 Thousand USD | 146.86% |
| 2010 Q1 | 4335.00 USD | 464.9% |
| 2010 FY | 36.96 Thousand USD | 151.35% |
| 2010 Q4 | 11.58 Thousand USD | -10.37% |
| 2010 Q3 | 12.92 Thousand USD | 59.13% |
| 2010 Q2 | 8123.00 USD | 87.38% |
| 2009 Q3 | 6451.00 USD | -22.23% |
| 2009 Q1 | 1150.00 USD | -65.61% |
| 2009 Q2 | 8295.00 USD | 621.3% |
| 2009 Q4 | -1188.00 USD | -118.42% |
| 2009 FY | 14.7 Thousand USD | 158.62% |
| 2008 Q4 | 3344.00 USD | 148.99% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | 5687.00 USD | 0.0% |
| 2008 Q3 | 1343.00 USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1359.041% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.738% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 109.611% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.974% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.119% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 163.632% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 124.714% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.795% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -889.942% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.686% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 53.28% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 189.921% |
| Mesoblast Limited | -35.16 Million USD | 100.087% |
| Marizyme, Inc. | 457.7 Thousand USD | 93.291% |
| Genus plc | 178.7 Million USD | 99.983% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.986% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 50.651% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 92.513% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 379.164% |
| ContraFect Corporation | -154 Thousand USD | 119.94% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 161.416% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 59.995% |
| IMV Inc. | -962.29 Thousand USD | 103.191% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 107.925% |
| MultiCell Technologies, Inc. | 49.32 USD | -62162.774% |
| ONE Bio Corp. | 20.12 Million USD | 99.847% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.924% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 37.202% |
| Q BioMed Inc. | -8988.00 USD | 441.656% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.891% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 299.092% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.931% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 102.69% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 56.131% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 720.113% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 78.144% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 131.491% |
| GB Sciences, Inc. | -624.00 USD | 5021.154% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 135.695% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 14863.462% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 93.635% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.997% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 105.968% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 95.026% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.993% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 446.748% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 136.623% |
| Kadimastem Ltd | -630.13 Thousand USD | 104.873% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 96.892% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.68% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.801% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 359.468% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 82.608% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 82.608% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 97.737% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 205.89% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 93.177% |
| SYBLEU INC | 11.69 Thousand USD | -162.551% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 99.334% |
| Bioxytran, Inc. | -8285.00 USD | 470.646% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 108.233% |
| Neutra Corp. | 14.33 Thousand USD | -114.217% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 137.449% |
| PureTech Health plc | -1.6 Million USD | 101.916% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 103.067% |
| IXICO plc | 3.27 Million USD | 99.061% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 104.425% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 101.715% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | -70.6% |